In agreement with these observations, Brieghel et al. [12] advocated the pre-treatment assessment of TP53 aberrations in CLL patients, highlighting the association between TP53 mutations and resistance to chemoimmunotherapy. This evidence concerns the gene TP53 and B-cell chronic lymphocytic leukemia.